Birchview Capital, LP Xencor Inc Transaction History

Birchview Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$7.52 - $11.26 $330,880 - $495,440	44,000 Added 169.23%	70,000 $550,000
Q4 2024 Jun 30, 2025	BUY	$19.43 - $26.84 $266,191 - $367,708	13,700 Added 111.38%	26,000 $597,000
Q4 2024 Feb 14, 2025	BUY	$19.43 - $26.84 $266,191 - $367,708	13,700 Added 111.38%	26,000 $597,000
Q3 2023 Jun 30, 2025	SELL	$20.08 - $25.39 $275,096 - $347,843	-13,700 Reduced 52.69%	12,300 $247,000
Q3 2017 Nov 02, 2017	BUY	$19.61 - $23.35 $241,203 - $287,205	12,300	12,300 $282,000

216

81.9M

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $891M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Birchview Capital, LP with notifications on news.